Soligenix, Inc. (SNGX)

Oncology Corporate Profile

Stock Performance

0.7410
-0.0360

3 Month Stock History Chart

HQ Location

29 Emmons Drive Suite C-10
Princeton, NJ 8540

Company Description

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Website: http://soligenix.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SGX301photodynamic therapyCutaneous T-Cell LymphomaIII
dusquetide / SGX942innate defense regulatorHead & Neck cancerIII

View additional information on product candidates here »

Source: http://soligenix.com

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/16/2017 06:19 am

8/14/2017 12:19 am

8/14/2017 12:19 am

8/14/2017 12:19 am

8/14/2017 12:19 am

8/14/2017 12:19 am

8/11/2017 12:19 am

8/11/2017 12:19 am

8/11/2017 12:19 am

8/11/2017 12:19 am

8/11/2017 12:19 am

8/9/2017 06:19 am

8/1/2017 06:19 pm

7/27/2017 06:19 am

7/18/2017 06:19 am

7/6/2017 12:19 am